Smallpox vaccine

AHF: Africa Needs Vaccines to Fight Mpox, Wealthy Countries Must Act

Retrieved on: 
Friday, October 13, 2023
Public Policy, Government, Health, Infectious Diseases, Advocacy Group Opinion, General Health, Pharmaceutical, Infection, COVID-19, Public, Vaccine, Democratic republic, AIDS Healthcare Foundation, AHF, Global North and Global South, World Health Organization, Policy, Solidarity, Mpox, Research, Smallpox vaccine

The Jynneos smallpox vaccine has proven effective in fighting mpox.

Key Points: 
  • The Jynneos smallpox vaccine has proven effective in fighting mpox.
  • “Even though the World Health Organization declared that mpox was no longer a public health emergency in May, Africans are threatened by an even deadlier strain that can kill up to 10% of those who contract it.
  • Additionally, Africa must have the resources to produce vaccines on the continent.
  • With these measures in place, governments will be better prepared for future outbreaks and can prevent them from becoming a global crisis.

Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-801 as a Potential Vaccine to Prevent Mpox and Smallpox

Retrieved on: 
Monday, August 21, 2023
Vaccine, Infection, Medicine, Vaccination, COVID-19, New Drug Application, Smallpox, Mpox, Global health, History, Animal, Risk, Smallpox vaccine, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Phenotype, Food, Safety, Disease, Pharmaceutical industry, COVID, Tonix Pharmaceuticals, IND

CHATHAM, N.J., Aug. 21, 2023 (GLOBE NEWSWIRE) --  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it received the official written response from a Type B pre-Investigational New Drug Application (IND) meeting with the U.S. Food and Drug Administration (FDA) to develop TNX-8011 (recombinant horsepox virus, live vaccine) as a potential vaccine to protect against mpox disease (formerly known as monkeypox) and smallpox. Tonix believes the FDA feedback provides a path to agreement on the design of a Phase 1/2 study and the overall clinical development plan. The Phase 1/2 clinical trial will assess the safety, tolerability, and immunogenicity of TNX-801, following the submission and clearance of an IND.

Key Points: 
  • Tonix believes the FDA feedback provides a path to agreement on the design of a Phase 1/2 study and the overall clinical development plan.
  • The Phase 1/2 clinical trial will assess the safety, tolerability, and immunogenicity of TNX-801, following the submission and clearance of an IND.
  • The “take” is a functional measure of protective T-cell immunity validated by the eradication of smallpox.
  • Live replicating vaccines have the potential to induce durable T-cell immunity, prevent serious illness after infection and block forward transmission.

Europe Monkeypox Testing Market Research Report 2023: An $18.33 Billion Market in 2022 - Industry Outlook and Forecasts to 2025 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 13, 2023
Biotechnology, Pharmaceutical, Health, Central African, Contact tracing, CE, European Commission, Smallpox vaccine, USD, Risk, Bavarian Nordic, European Medicines Agency, Government, NAAT, Research, European, Monkeypox virus, IVD, Orthopoxvirus, Pregnancy, MPXV, NHS, MPX, Division of Acquired Immunodeficiency Syndrome, Standing Commission on Pay Comparability, DNA, PCR, Growth, Civil service commission, Partnership, Joint Committee on Vaccination and Immunisation, National Health Service, Infection, Privacy and the US government, Cepheid (company), Mpox, Cepheid variable, Roche, EMA, Person, Vaccine, Viral, Medical device, Pharmaceutical industry, Vaccination, EU

The "Europe Monkeypox Testing Market - Industry Outlook and Forecast 2023-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Monkeypox Testing Market - Industry Outlook and Forecast 2023-2025" report has been added to ResearchAndMarkets.com's offering.
  • The Europe monkeypox testing market was valued at USD 18,330.00 thousand in 2022 and is expected to reach USD 56.10 thousand by 2025.
  • Increasing cases and testing are driving the growth of the Europe monkeypox testing market.
  • The growing product launches of lateral flow assay kits are expected to create lucrative opportunities for the Europe monkeypox testing market growth.

AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

Retrieved on: 
Thursday, December 8, 2022
Smallpox vaccine, Event, RNA, B cell, Immunology, Society, Chronic fatigue syndrome, CFS, Special access program, EAP, NYSE, Influenza and Other Respiratory Viruses, Pancreatic cancer, RANTES, AES, British Society for Research on Ageing, Safety, Physician, Monocyte, AIM, Degenerative disease, Erasmus MC, TNF, Vaccinia, IL-8, Chemokine, Inspectorate, ME/CFS, TLR3, PSLRA, IL-6, Infection, Patient, CXCL10, Immune system, Research, Disease, Interferon, Cancer, Severe acute respiratory syndrome coronavirus 2, COVID-19, CHDR, Granulocyte, Therapy, Vaccine, Pharmaceutical industry, Rintatolimod, MCP-1

OCALA, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today reported that data were recently presented by Lisanne C.A. Smidt - Centre for Human Drug Research (CHDR), Leiden, the Netherlands in a poster titled, “Safety, tolerability and biological activity of repeated intranasal administration of TLR3 agonist Ampligen (Poly I:Poly C12U) in healthy subjects,” at the British Society for Immunology Congress 2022 . The data showed positive safety, tolerability and biological activity of a 13-day dosing regimen conducted in Q2 2021 for intranasal Ampligen® (rintatolimod) in healthy subjects.

Key Points: 
  • Smidt - Centre for Human Drug Research (CHDR), Leiden, the Netherlands in a poster titled, “Safety, tolerability and biological activity of repeated intranasal administration of TLR3 agonist Ampligen (Poly I:Poly C12U) in healthy subjects,” at the British Society for Immunology Congress 2022 .
  • The data showed positive safety, tolerability and biological activity of a 13-day dosing regimen conducted in Q2 2021 for intranasal Ampligen® (rintatolimod) in healthy subjects.
  • Intranasal administration of Ampligen could induce an innate mucosal immune response, thereby inhibiting respiratory viruses at the point of entry.
  • Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA.

AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease

Retrieved on: 
Wednesday, November 2, 2022
AIM, Inspectorate, Vaccinia, ME/CFS, Ebola, Pancreatic cancer, Chronic fatigue syndrome, Food and Drug Administration, GLOBE, Research, NYSE, Degenerative disease, COVID-19, Program, Disease, Orphan drug, Special access program, Person, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Immune system, Erasmus MC, EVD, EAP, Safety, Condition, Company, Centers for Disease Control and Prevention timeline, Cancer, FDA, Patient, Food, American, CFS, ACHES, Fever, Smallpox vaccine, CDC, Severe acute respiratory syndrome coronavirus 2, Therapy, AIM ImmunoTech, Diagnosis, Vaccine, Pharmaceutical industry, Rintatolimod

OCALA, Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Ampligen® (rintatolimod) for the treatment of Ebola virus disease.

Key Points: 
  • Ampligen is AIMs dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
  • Receiving Orphan Drug Designation for Ampligen for the treatment of Ebola from the FDA is a testament to the depth and breadth of the potential with Ampligen.
  • We continue to be encouraged by the promising results Ampligen has demonstrated to date across a number of indications where there remains significant unmet need.
  • Ebola virus disease (EVD) is a rare but severe, deadly disease causing a multitude of symptoms including fever, gastrointestinal issues, aches, and bruising.1 Previous animal studies yielded positive results utilizing Ampligen in Western Equine Encephalitis Virus, Ebola, Vaccinia Virus (which is used in the manufacture of smallpox vaccine) and SARS-CoV-1.

Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines

Retrieved on: 
Tuesday, November 1, 2022
Marketing, Emergent, Life, CHIKV, Emergent BioSolutions, Myalgia, Tropical medicine, Chikungunya, VLP, SEC, GLOBE, Society, NYSE, National Institute, SVP, Walter Reed Army Institute of Research, Program, Rash, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Breakthrough therapy, EBS, PRIME, Army, Priority, Public health, National Institute of Allergy and Infectious Diseases, Safety, Incidence, Infection, National, Vaccine, Private Securities Litigation Reform Act, European Medicines Agency, Food, Alphavirus, Fast Track, Smallpox vaccine, Fever, Solution, 2020 European Medicines Agency cyberattack, Military personnel, Headache, Therapy, Venezuela, Seroconversion, Risk, Pharmaceutical industry, Hygiene

This Phase 2 parallel group, age- and gender-matched, open-label study evaluating the safety and immunogenicity of an adjuvanted CHIKV VLP vaccine candidate in prior recipients of experimental alphavirus vaccines, in comparison to a cohort of alphavirus vaccine-nave individuals, enrolled 60 healthy adults at two U.S. sites.

Key Points: 
  • This Phase 2 parallel group, age- and gender-matched, open-label study evaluating the safety and immunogenicity of an adjuvanted CHIKV VLP vaccine candidate in prior recipients of experimental alphavirus vaccines, in comparison to a cohort of alphavirus vaccine-nave individuals, enrolled 60 healthy adults at two U.S. sites.
  • A higher percentage of prior alphavirus vaccine candidate recipients had a four-fold rise on study day 8 than the alphavirus vaccine-nave group.
  • In addition to the oral presentation on the chikungunya vaccine candidate, Emergent has poster presentations on its smallpox vaccine, cholera vaccine, and Lassa fever vaccine candidate.
  • Emergent BioSolutions CHIKV VLP chikungunya virus vaccine candidate is a single dose VLP-based vaccine in clinical development for active immunization against chikungunya disease.

Bavarian Nordic Awarded Ten-Year Contract Amendment valued up to USD 434 million for the Supply of Smallpox and Monkeypox Vaccine to Canada

Retrieved on: 
Tuesday, September 20, 2022
Smallpox vaccine, Public Health Agency of Canada, PHAC, COVID-19, Tick-borne encephalitis, FDA, Food, DND, Vaccination, European Commission, Janssen Pharmaceuticals, Population, Forward-looking statement, Government, USD, Regulation of tobacco by the U.S. Food and Drug Administration, Johnson & Johnson, Rabies, Public Health Agency, Health Canada, Vaccine, Immunodeficiency, Goal, National security, OMX, Smallpox, Royal commission, Monkeypox, Immune system, Modified vaccinia Ankara, Cryptocurrency, Bavarian Nordic

This extends the USD 56 million contract awarded in June 2022 to a total value of up to USD 470 million.

Key Points: 
  • This extends the USD 56 million contract awarded in June 2022 to a total value of up to USD 470 million.
  • Furthermore, a new multi-year contract has been signed with Canadas Department of National Defence (DND) at a value of USD 2 million, in addition to USD 18 million in contract options.
  • Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic, said: With foresight and prioritization, Canada has shown the way to building a robust preparedness for its population.
  • The vaccine is also approved for protection against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe.

National Diaper Bank Network joins national COVID-19 vaccination campaign

Retrieved on: 
Tuesday, September 13, 2022
Smallpox vaccine, American Academy, Health, Burt, Joseph Keppler, COVID-19, Nursing, Office of Inspector General, U.S. Department of Health and Human Services, Meal, Pediatrics, Seventh-day Adventist Church, American Red Cross, United Way, Organization, Vaccination, Orange County, Life, Foot, Partnership, COVID, Foundation, U.S. Department of Defense Strategy for Operating in Cyberspace, World Red Cross and Red Crescent Day, National Diaper Bank Network, AARP, National, Human services, Vaccine, Family, Insurance, LDS Family Services, Hepatitis A, Parent, Smallpox, American Academy of Pediatrics, Disease, Internet access, Pharmaceutical industry, Animal, Wool, Citrus, HAVEN

NEW HAVEN, Conn., Sept. 13, 2022 /PRNewswire/ -- The National Diaper Bank Network (NDBN) is getting information about COVID vaccines into hard-to-reach neighborhoods as a community partner with the U.S. Department of Health and Human Services' We Can Do This campaign. The effort comes as NDBN members have already increased by 86% the volume of diapers, period supplies, and other material basic necessities they provide, in response to the pandemic. 

Key Points: 
  • For Northern Virginia Diaper Bank Program Director Susan Mullen, freeing communities from disease runs in the family.
  • The National Diaper Bank Network (NDBN) provides material basic necessities required to build the strong foundations all children, families, and individuals require to thrive and reach their full potential.
  • Wework in partnership with our Network of diaper banks, allied programs, donors, sponsors, and elected officials to enddiaperneedandperiod povertyin the United States.
  • Diaper banksparticipating in the campaign include:
    Bundles of Hope Diaper Bank, Birmingham
    Diaper Bank of Southern Arizona, Tucson
    Community Action Partnership of Orange County, Garden Grove
    Open Arms Food Pantry and Resource Center, Los Angeles
    Sacramento Food Bank & Family Services, Sacramento
    United Way of Weld County Covering Weld Diaper Bank, Greeley
    The Diaper Bank of Connecticut, North Haven
    The Greater Fort Lauderdale Diaper Bank, Cooper City
    Diaper Bank for Northeast Florida, Orange Park

United Kingdom Monkeypox Therapeutics Market Analysis Report 2022: Focus on Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin (VIG) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 6, 2022
Health, Pharmaceutical, Treatment, Research, Disorder, Monkeypox virus, Immunity, Awareness, Bolt-on acquisition, Hospital, Wilford Hall Ambulatory Surgical Center, SIGA Technologies, Emergent, Therapy, Population, Alembic Pharmaceuticals, Knowledge, Growth, Monkeypox, Patient, Smallpox vaccine, Vaccine, Pharmaceutical industry, Fine chemical, Medical device, Generic drug

The United Kingdom monkeypox therapeutics market is segmented on the basis of treatment, end user, regional distribution, and competitive landscape.

Key Points: 
  • The United Kingdom monkeypox therapeutics market is segmented on the basis of treatment, end user, regional distribution, and competitive landscape.
  • To estimate and forecast the market size of United Kingdom monkeypox therapeutics market from 2023 to 2027 and growth rate until 2027.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the United Kingdom monkeypox therapeutics market.
  • To identify key sustainable strategies adopted by market players in United Kingdom monkeypox therapeutics market.

Bavarian Nordic Enters Supply Agreement with PAHO to Support Access to Monkeypox Vaccines in Latin America and the Caribbean

Retrieved on: 
Wednesday, August 24, 2022
COVID-19, CEO, PAHO, Tick-borne encephalitis, Vaccination, Janssen Pharmaceuticals, Regulation of tobacco by the U.S. Food and Drug Administration, Government, WHO, Vaccine, Modified vaccinia Ankara, Global health, OMX, Food, Organic, Smallpox vaccine, Royal commission, Health Canada, Rabies, Goal, Organization, Bavarian Nordic, Access, FDA, Immune system, Population, Smallpox, World, Immunodeficiency, Johnson & Johnson, Pan American Health Organization, European Commission, Health, Monkeypox, Forward-looking statement, Region, World Health Organization

COPENHAGEN, Denmark, August 24, 2022 Bavarian Nordic A/S (OMX: BAVA) announced today an agreement with the Pan American Health Organization (PAHO) to facilitate equitable access to the Companys monkeypox vaccine for countries in Latin America and the Caribbean.

Key Points: 
  • COPENHAGEN, Denmark, August 24, 2022 Bavarian Nordic A/S (OMX: BAVA) announced today an agreement with the Pan American Health Organization (PAHO) to facilitate equitable access to the Companys monkeypox vaccine for countries in Latin America and the Caribbean.
  • With the agreement, we have now helped to secure access to our vaccine in more than 70 countries globally, representing the vast majority of affected regions outside endemic areas.
  • Bavarian Nordic maintains its guidance for 2022 as this order has already been included in the upgraded financial expectations, as communicated on July 18, 2022.
  • Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines.